Document text
Principal Investigator: Hadi Mohammadigoushki
Organization: FLORIDA STATE UNIVERSITY
Fiscal Year: 2024
Award: $189,456
Funding agency: National Institute of Allergy and Infectious Diseases
PROJECT SUMMARY/ABSTRACT
Monoclonal antibodies (mAbs) represent an important class of biologic therapeutics that can
treat COVID-19, cancer and other infectious diseases. Despite their promising potential, pro-
cessing, storage and/or administration of mAbs into patients is challenging because the presence
of hydrophobic interfaces during processing and administration (air entrapment in the IV bags
or the oil-water interface at the interior of syringes) may promote mAb adsorption to such hy-
drophobic interfaces. If mAbs change their native (folded) higher order structures (HOS) upon
adsorption to these interfaces, their quality, safety and efficacy will be affected, posing immuno-
genicity risks to already susceptible patients. The first step in mitigating these risks is to evaluate
the in situ HOS of mAbs (whether folded or unfolded) at hydrophobic interfaces. Determining the
in situ structure of mAbs at such interfaces has been a major challenge due to limitations of bulk
scale or scattering-based microstructural probing techniques. In this program, we will go beyond
such limits and use a combination of a unique molecular probing technique based on NMR spec-
troscopy and dynamic surface tensiometry to resolve the details of mAbs HOS and adsorption
kinetics at hydrophobic interfaces. In particular, by using high-field spatially and spectrally re-
solved NMR spectroscopy that is uniquely available to use through National High Magnetic Field
Laboratory, we will assess dynamically 1) the in situ HOS of pure mAbs at hydrophobic interfaces,
and 2) nature of their associations with surfactants at interfaces. We will perform tensiometry
along with NMR spectroscopy on pure mAbs, isotopically labeled mAbs and mAbs/surfactant
combinations at hydrophobic interfaces. We will measure a) dynamic surface tension, b) spa-
tially localized chemical shifts in 1D 1H and 2D 1H-13C NMR spectra, c) diffusion coefficients of
the mAbs, and d) T2 relaxation of mAbs in the bulk and at the interface under different conditions
(e.g., various mAbs and surfactant concentrations, solution pH and ionic strengths). By compar-
ing the results of the bulk and interface in terms of metrics (a-d), the team will determine if the
native HOS of mAbs has been altered by adsorption to hydrophobic interfaces or their associa-
tions with surfactants. The outcome of this study will provide the first mechanistic understanding
of mAbs HOS at hydrophobic interfaces. Additionally, the knowledge gained from this research
is essential in developing a framework to mitigate mAbs adsorption to hydrophobic interfaces,
which can be subsequently utilized to improve efficacious mAb deployment for patients.
1
Terms: <4-O-alpha-D-glucopyranosyl-D-glucose><Adsorption><Affect><Air><Autoimmune Diseases><Binding><Biological Response Modifier Therapy><Biological Therapy><COVID-19><COVID-19 therapy><COVID-19 treatment><CV-19><Cancer Treatment><Cancers><Cardiovascular Diseases><Chemicals><Clinical Treatment Moab><Communicable Diseases><Coronavirus Infectious Disease 2019><Development><Diffusion><Drugs><Formulation><Foundations><Frequencies><Future><Grant><Higher Order Chromatin Folding><Higher Order Chromatin Structure><Higher Order Structure><Hydrogen Oxide><Hydrophobicity><In Situ><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Ionic Strengths><Isotope Labeling><Kinetics><Knowledge><Laboratories><Life><Location><MERS corona virus><MERS coronavirus><MERS virus><MERS-CoV><MR Imaging><MR Tomography><MRI><MRIs><Magnetic Resonance Imaging><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Maltose><Measurement><Measures><Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance><Medication><Middle East Respiratory Syndrome Corona Virus><Middle East Respiratory Syndrome Coronavirus><Middle East Respiratory Syndrome Virus><Middle East Respiratory Syndrome-CoV><Middle East Respiratory Virus><Middle East Respiratory coronavirus><Middle Eastern Respiratory Syndrome Corona virus><Middle Eastern Respiratory Syndrome Coronavirus><Middle Eastern Respiratory Syndrome Virus><Middle Eastern Respiratory Syndrome-CoV><Modeling><Molecular><Molecular Interaction><Molecular Probe Technics><Molecular Probe Techniques><Monoclonal Antibodies><NMR Imaging><NMR Spectrometer><NMR Spectroscopy><NMR Tomography><Nature><Neutrons><Nuclear Magnetic Resonance><Nuclear Magnetic Resonance Imaging><Oils><Outcome Study><PSML><Patients><Pharmaceutical Preparations><Polyoxyethylene Sorbitan Monolaurate><Polysorbates><Predisposition><Proteins><Relaxation><Research><Resolution><Risk><Roentgen Rays><SARS Virus><SARS corona virus><SARS coronavirus><SARS-Associated Coronavirus><SARS-CoV><SARS-CoV-1><SARS-CoV-2 therapy><SARS-CoV-2 treatment><SARS-Related Coronavirus><Safety><Severe Acute Respiratory Coronavirus><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Spectroscopy><Spectrum Analyses><Spectrum Analysis><Structure><Surface><Surface Tension><Susceptibility><Syringes><System><Techniques><Temperature><Testing><Therapeutic><Time><Transportation><Viral><Viral Diseases><Virus Diseases><Water><X-Radiation><X-Ray Radiation><X-ray><Xray><Zeugmatography><anti-cancer therapy><autoimmune condition><autoimmune disorder><autoimmunity disease><biological therapeutic><biological treatment><biologically based therapeutics><bioprocess><biotherapeutics><biotherapy><cancer therapy><cancer-directed therapy><cardiovascular disorder><coronavirus disease 2019><coronavirus disease 2019 therapy><coronavirus disease 2019 treatment><coronavirus disease-19><coronavirus infectious disease-19><developmental><diffused><diffuses><diffusing><diffusions><drug/agent><experience><immunogenicity><improved><indexing><interfacial><mAbs><macromolecule><magnetic field><malignancy><monoclonal Abs><native protein drug><neoplasm/cancer><novel><nuclear magnetic resonance spectroscopy><pharmaceutical protein><programs><protein drug agent><protein-based drug><quantum><resolutions><risk mitigation><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 treatment><severe acute respiratory syndrome-CoV><surfactant><therapeutic protein><treat COVID-19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><viral infection><virus infection><virus-induced disease>